401 related articles for article (PubMed ID: 33268562)
1. Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study.
Naismith RT; Bermel RA; Coffey CS; Goodman AD; Fedler J; Kearney M; Klawiter EC; Nakamura K; Narayanan S; Goebel C; Yankey J; Klingner E; Fox RJ;
Neurology; 2021 Jan; 96(4):e491-e500. PubMed ID: 33268562
[TBL] [Abstract][Full Text] [Related]
2. Effects of Ibudilast on Retinal Atrophy in Progressive Multiple Sclerosis Subtypes: Post Hoc Analyses of the SPRINT-MS Trial.
Ehrhardt H; Lambe J; Moussa H; Vasileiou ES; Kalaitzidis G; Murphy OC; Filippatou AG; Pellegrini N; Douglas M; Davis S; Nagy N; Quiroga A; Hu C; Zambriczki Lee A; Duval A; Fitzgerald KC; Prince JL; Calabresi PA; Sotirchos ES; Bermel R; Saidha S
Neurology; 2023 Sep; 101(10):e1014-e1024. PubMed ID: 37460235
[TBL] [Abstract][Full Text] [Related]
3. Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.
Nakamura K; Thoomukuntla B; Bena J; Cohen JA; Fox RJ; Ontaneda D
Mult Scler; 2024 Mar; 30(3):369-380. PubMed ID: 38286755
[TBL] [Abstract][Full Text] [Related]
4. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
Barkhof F; Hulst HE; Drulovic J; Uitdehaag BM; Matsuda K; Landin R;
Neurology; 2010 Mar; 74(13):1033-40. PubMed ID: 20200338
[TBL] [Abstract][Full Text] [Related]
5. Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.
Nakamura K; Zheng Y; Mahajan KR; Cohen JA; Fox RJ; Ontaneda D
Mult Scler; 2023 Sep; 29(10):1257-1265. PubMed ID: 37537928
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.
Fox RJ; Coffey CS; Conwit R; Cudkowicz ME; Gleason T; Goodman A; Klawiter EC; Matsuda K; McGovern M; Naismith RT; Ashokkumar A; Barnes J; Ecklund D; Klingner E; Koepp M; Long JD; Natarajan S; Thornell B; Yankey J; Bermel RA; Debbins JP; Huang X; Jagodnik P; Lowe MJ; Nakamura K; Narayanan S; Sakaie KE; Thoomukuntla B; Zhou X; Krieger S; Alvarez E; Apperson M; Bashir K; Cohen BA; Coyle PK; Delgado S; Dewitt LD; Flores A; Giesser BS; Goldman MD; Jubelt B; Lava N; Lynch SG; Moses H; Ontaneda D; Perumal JS; Racke M; Repovic P; Riley CS; Severson C; Shinnar S; Suski V; Weinstock-Guttman B; Yadav V; Zabeti A;
N Engl J Med; 2018 Aug; 379(9):846-855. PubMed ID: 30157388
[TBL] [Abstract][Full Text] [Related]
7. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.
Fox RJ; Coffey CS; Cudkowicz ME; Gleason T; Goodman A; Klawiter EC; Matsuda K; McGovern M; Conwit R; Naismith R; Ashokkumar A; Bermel R; Ecklund D; Koepp M; Long J; Natarajan S; Ramachandran S; Skaramagas T; Thornell B; Yankey J; Agius M; Bashir K; Cohen B; Coyle P; Delgado S; Dewitt D; Flores A; Giesser B; Goldman M; Jubelt B; Lava N; Lynch S; Miravalle A; Moses H; Ontaneda D; Perumal J; Racke M; Repovic P; Riley C; Severson C; Shinnar S; Suski V; Weinstock-Gutman B; Yadav V; Zabeti A
Contemp Clin Trials; 2016 Sep; 50():166-77. PubMed ID: 27521810
[TBL] [Abstract][Full Text] [Related]
8. Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis.
Ladakis DC; Reyes-Mantilla MI; Gadani SP; Mace JW; Dominguez-Penuela SC; Appiah MJ; Smith MD; Bhargava P; Fox RJ; Saidha S; Calabresi PA
Mult Scler; 2024 Jan; 30(1):35-43. PubMed ID: 37982154
[TBL] [Abstract][Full Text] [Related]
9. Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype.
Goodman AD; Fedler JK; Yankey J; Klingner EA; Ecklund DJ; Goebel CV; Bermel RA; Chase M; Coffey CS; Klawiter EC; Naismith RT; Fox RJ;
Ann Clin Transl Neurol; 2021 Jan; 8(1):111-118. PubMed ID: 33460301
[TBL] [Abstract][Full Text] [Related]
10. The effect of ibudilast on thalamic volume in progressive multiple sclerosis.
Nicholson S; Russo AW; Brewer K; Bien H; Tobyne SM; Eloyan A; Klawiter EC
Mult Scler; 2023 Dec; 29(14):1819-1830. PubMed ID: 37947294
[TBL] [Abstract][Full Text] [Related]
11. Ibudilast for the treatment of multiple sclerosis.
Goodman AD; Gyang T; Smith AD
Expert Opin Investig Drugs; 2016 Oct; 25(10):1231-7. PubMed ID: 27501293
[TBL] [Abstract][Full Text] [Related]
12. Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.
Bermel RA; Fedler JK; Kaiser P; Novalis C; Schneebaum J; Klingner EA; Williams D; Yankey JW; Ecklund DJ; Chase M; Naismith RT; Klawiter EC; Goodman AD; Coffey CS; Fox RJ
Mult Scler; 2021 Aug; 27(9):1384-1390. PubMed ID: 33054533
[TBL] [Abstract][Full Text] [Related]
13. Number of MRI T1-hypointensity corrected by T2/FLAIR lesion volume indicates clinical severity in patients with multiple sclerosis.
Akaishi T; Takahashi T; Fujihara K; Misu T; Mugikura S; Abe M; Ishii T; Aoki M; Nakashima I
PLoS One; 2020; 15(4):e0231225. PubMed ID: 32243459
[TBL] [Abstract][Full Text] [Related]
14. Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
Cree BAC; Bowen JD; Hartung HP; Vermersch P; Hughes B; Damian D; Hyvert Y; Dangond F; Galazka A; Grosso M; Jones DL; Leist TP
Mult Scler Relat Disord; 2021 Apr; 49():102695. PubMed ID: 33578191
[TBL] [Abstract][Full Text] [Related]
15. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL
Brain; 2019 Sep; 142(9):2787-2799. PubMed ID: 31497864
[TBL] [Abstract][Full Text] [Related]
16. Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG
Arnold DL; Banwell B; Bar-Or A; Ghezzi A; Greenberg BM; Waubant E; Giovannoni G; Wolinsky JS; Gärtner J; Rostásy K; Krupp L; Tardieu M; Brück W; Stites TE; Pearce GL; Häring DA; Merschhemke M; Chitnis T;
J Neurol Neurosurg Psychiatry; 2020 May; 91(5):483-492. PubMed ID: 32132224
[TBL] [Abstract][Full Text] [Related]
17. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S
BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571
[TBL] [Abstract][Full Text] [Related]
18. Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy.
Stevenson VL; Smith SM; Matthews PM; Miller DH; Thompson AJ
J Neurol; 2002 Feb; 249(2):171-7. PubMed ID: 11985382
[TBL] [Abstract][Full Text] [Related]
19. Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity.
Regev K; Healy BC; Khalid F; Paul A; Chu R; Tauhid S; Tummala S; Diaz-Cruz C; Raheja R; Mazzola MA; von Glehn F; Kivisakk P; Dupuy SL; Kim G; Chitnis T; Weiner HL; Gandhi R; Bakshi R
JAMA Neurol; 2017 Mar; 74(3):275-285. PubMed ID: 28114622
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
